Literature DB >> 25128508

Percutaneous transluminal angioplasty for symptomatic pulmonary stenosis in Takayasu arteritis.

Hui Dong1, Xiongjing Jiang2, Meng Peng1, Yubao Zou1, Ting Guan1, Huimin Zhang1, Lei Song1, Haiying Wu1, Yuejin Yang1, Runlin Gao1.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the safety and efficacy of percutaneous transluminal angioplasty (PTA) for symptomatic pulmonary stenosis in Takayasu arteritis (TA).
METHODS: From January 2009 to December 2012, clinical data of 14 patients [mean age 33.9 ± 9.3 yrs; 11 patients female (78.6%)] with symptomatic pulmonary stenosis in TA underwent PTA and were analyzed prospectively.
RESULTS: PTA was successfully performed in 22 lesions of 14 patients. Among those lesions, 18 were treated by PTA alone while the others were treated with stent implantation. Three patients (21.4%) had reperfusion pulmonary injury; 2 patients recovered completely while the other died of respiratory failure 3 days after the procedure. Mean pulmonary arterial pressure (PAP) decreased from 53.4 ± 15.8 mmHg to 38.4 ± 12.7 mmHg immediately after intervention (p < 0.001). After an average of 29 months of followup, the New York Heart Association functional class and 6-min walking distances improved while mean PAP measured by echocardiography decreased significantly (compared with baseline, all p < 0.01). One patient died of severe pulmonary infection and cardiac shock at 28 months after the procedure.
CONCLUSION: The study showed that PTA improved subjective symptoms and objective variables of the patients with symptomatic pulmonary stenosis in TA, with an acceptable mortality. PTA may be a promising therapeutic strategy for symptomatic pulmonary stenosis in TA.

Entities:  

Keywords:  PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PULMONARY STENOSIS; TAKAYASU ARTERITIS

Mesh:

Year:  2014        PMID: 25128508     DOI: 10.3899/jrheum.131007

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Vascular surgery: the main risk factor for mortality in 146 Takayasu arteritis patients.

Authors:  Nilton Salles Rosa Neto; Samuel Katsuyuki Shinjo; Maurício Levy-Neto; Rosa Maria Rodrigues Pereira
Journal:  Rheumatol Int       Date:  2017-02-21       Impact factor: 2.631

Review 2.  Cardiac involvement in primary systemic vasculitis and potential drug therapies to reduce cardiovascular risk.

Authors:  Durga Prasanna Misra; Sajjan N Shenoy
Journal:  Rheumatol Int       Date:  2016-02-17       Impact factor: 2.631

Review 3.  Successful Early Immunosuppressive Therapy for Pulmonary Arterial Hypertension Due to Takayasu arteritis: Two Case Reports and a Review of Similar Case Reports in the English Literature.

Authors:  Takuya Suda; Takeshi Zoshima; Kiyoaki Ito; Ichiro Mizushima; Mitsuhiro Kawano
Journal:  Intern Med       Date:  2021-11-13       Impact factor: 1.282

4.  Heart Failure in a Child: Multimodality Approach Leading to an Unusual Cause.

Authors:  Uma Devi Karuru; Jay Relan; Mansi Verma; Sanjeev Kumar; Madhavi Tripathi; Saurabh Kumar Gupta; Sivasubramanian Ramakrishnan; Anita Saxena; Shyam S Kothari
Journal:  JACC Case Rep       Date:  2021-12-01

5.  Long-Term Outcomes After Percutaneous Transluminal Pulmonary Angioplasty in Patients With Takayasu Arteritis and Pulmonary Hypertension.

Authors:  Zhiwei Huang; Man Wang; Fenghuan Hu; Xiaoning Liu
Journal:  Front Immunol       Date:  2022-03-11       Impact factor: 7.561

6.  Management of Takayasu arteritis: a systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis.

Authors:  Ana F Águeda; Sara Monti; Raashid Ahmed Luqmani; Frank Buttgereit; Maria Cid; Bhaskar Dasgupta; Christian Dejaco; Alfred Mahr; Cristina Ponte; Carlo Salvarani; Wolfgang Schmidt; Bernhard Hellmich
Journal:  RMD Open       Date:  2019-09-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.